Methodist Dallas Medical Center
Welcome,         Profile    Billing    Logout  
 29 Trials 
30 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lin, Feng
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C

Recruiting
2/3
520
RoW
HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo
Sunshine Lake Pharma Co., Ltd.
Chronic HCV Infection
04/23
04/23
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed
2
250
RoW
GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table
Sunshine Lake Pharma Co., Ltd.
Chronic HBV Infection
06/22
09/23
NCT05970666: Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Recruiting
2
71
RoW
TACE with adebrelimab and bevacizumab
The First Affiliated Hospital of Xiamen University, Jiangsu HengRui Medicine Co., Ltd.
Adebrelimab, Hepatocellular Carcinoma, Transformation, Bevacizumab, TACE
11/26
11/26
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Hepatocellular Carcinoma
03/26
03/26
Patel, Chirag
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05305365: Study Assessing QBS72S For Treating Brain Metastases

Recruiting
2
40
US
QBS72S, QBS10072S
Melanie Hayden Gephart, Quadriga Biosciences, Inc.
Brain Metastases, Breast Cancer
02/25
08/26
Mantry, Parvez
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Terminated
4
6
US
Placebo, Rifaximin, XIFAXAN® Tablets
Bausch Health Americas, Inc.
Hepatic Encephalopathy
02/16
02/16
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NAVIGATE, NCT04365868: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis

Active, not recruiting
2b
357
Europe, Canada, US, RoW
belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo
Galectin Therapeutics Inc.
Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis
12/24
12/24
FRESH, NCT05639543: FXR Effect on Severe Alcohol-Associated Hepatitis () Study

Recruiting
2
50
Europe, US
INT-787, Placebo
Intercept Pharmaceuticals
Alcohol Associated Hepatitis
12/24
12/24
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
PACIFIC, NCT05525520: Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

Active, not recruiting
2
58
Europe, Canada, US, RoW
EP547, Placebo
Escient Pharmaceuticals, Inc
Pruritus
07/24
09/24
NCT05239468: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Active, not recruiting
2
60
US
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Intercept Pharmaceuticals
Primary Biliary Cholangitis
11/24
02/25
NCT04595825: CM-101 in PSC Patients -The SPRING Study

Active, not recruiting
2
68
Europe, US, RoW
Anti-human CCL24 monoclonal antibody (CM-101), Placebo
ChemomAb Ltd.
Primary Sclerosing Cholangitis
09/24
09/25
VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/25
11/25
FOENIX-CCA4, NCT05727176: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Recruiting
2
120
Europe, Japan, US, RoW
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
06/25
06/26
HORIZON, NCT05583344: Phase 2b Study of GSK4532990 in Adults With NASH

Recruiting
2
246
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Nonalcoholic Fatty Liver Disease
09/25
12/25
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

Recruiting
N/A
100
US
Resin microspheres containing yttrium-90 (Y-90)
Sirtex Medical, Bright Research Partners
Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
06/24
06/25
Ebuh, Valentine
NCT05590403 / 2022-001981-36: A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Completed
3
1544
Europe, Canada, Japan, US, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/23
04/24
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

Completed
3
4223
Europe, US
ABNCoV2, Comirnaty
Bavarian Nordic
COVID-19 Disease
03/23
10/23
Brown, Crystal
NCT05406778: SPARK Neuro REMIND Study

Recruiting
N/A
800
US
SPARK Test
Spark Neuro Inc.
Alzheimer Disease, Cognitive Impairment
05/25
11/25
DiPasquale, Allison
RCT, NCT05113927: Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.

Recruiting
N/A
531
US
Selene
Perimeter Medical Imaging, Cancer Prevention Research Institute of Texas, Proxima Clinical Research, Biostatistical Consulting, Inc.
Breast Cancer
10/24
01/25
Martinez, Esmeralda
OnPrime, NCT05281471: Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (, GOG-3076)

Recruiting
3
186
US
olvimulogene nanivacirepvec, GL-ONC1 and GLV-1h68, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar)
Genelux Corporation, GOG Foundation
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma
08/25
10/26
Ndjom, Colette Ngo
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
NCT06093776: Rib Fracture Cryoanalgesia

Recruiting
N/A
10
US
ioveraº system
Methodist Health System, Pacira Pharmaceuticals, Inc
Pain Management Improvement
06/24
06/25
Bhatti, Mehreen
NCT05399537: Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

Recruiting
3
40
US
Prismocitrate 18
Baxter Healthcare Corporation
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
09/25
09/25
McDaniel, Conner
NCT06093776: Rib Fracture Cryoanalgesia

Recruiting
N/A
10
US
ioveraº system
Methodist Health System, Pacira Pharmaceuticals, Inc
Pain Management Improvement
06/24
06/25
Brauer, Bethany
VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
Donald, Reed
No trials found
Proffitt, Melanie
No trials found
Bageac, Alejandro
No trials found
Trussell, Joshua
No trials found
Loncharic, Erin
No trials found
Bedell, Loretta W
No trials found
Dowden, Andrew
No trials found
Ndjom, Bethany Ngo
No trials found
Bowen, Luis
No trials found

Download Options